EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa

Marian Loveday iD, Emma Clarence iD, Sindisiwe Hlangu, Nalini Singh, Sunitha Chotoo, James C M Brust iD, Catriona Waitt iD, Richard Court iD, Jennifer Furin

Clinical Infectious Diseases · 20.05.2026 · 82 (5) · e1063-e1071

DOI: 10.1093/cid/ciag032 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 22.01.2026. Verfasst von Marian Loveday und 8 weiteren Autor:innen. Beteiligte Einrichtung: HIV and Other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Antitubercular Agents, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is limited experience of the all-oral 6-month regimens containing bedaquiline, delamanid, linezolid, and levofloxacin or clofazimine (BDLLfx/BDLCfz) in pregnant women with multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB). We report maternal treatment, pregnancy, and infant outcomes to 12 months of age in a cohort of pregnant women treated with these regimens.

Methods

We included pregnant women treated for MDR/RR-TB from September 2023 to January 2025 in KwaZulu-Natal, South Africa, in a prospective observational study. Outcomes were collected through ongoing record reviews. Infant clinical assessments were conducted at 6 weeks, 6 months, and 12 months.

Results

Of 25 pregnant women with MDR/RR-TB, 21 received BDLLfx/BDLCfz; 12 (57%) were diagnosed with human immunodeficiency virus. Although 10 of the 21 (48%) treated women developed anemia, 18 (86%) had favorable treatment outcomes. All 21 infants were born alive, with a median gestational age 39 weeks (interquartile range [IQR], 38–40 weeks) and median birth weight 3160 g (IQR, 2818–3308 g). Three women had unfavorable pregnancy outcomes, with infants born prematurely (2 with low birth weight and 1 who developed respiratory distress syndrome). Of the 18 infants evaluated at 12 months, 10 (56%) had possible or confirmed unfavorable outcomes. Two infants had confirmed congenital anomalies and 3 possible congenital anomalies, but only 1 had first-trimester drug exposure. One infant died, another was diagnosed with MDR/RR-TB and started on treatment, and 3 infants had signs/symptoms of tuberculosis, necessitating referral for care.

Conclusions

These limited data suggest that in pregnant women, the BDLLfx/BDLCfz regimens have improved treatment and pregnancy outcomes compared to prior regimens. However, there is a high prevalence of unfavorable infant outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, Multidrug-ResistantAntitubercular AgentsPregnancy Complications, InfectiousHumansFemaleSouth AfricaPregnancyAdultRifampinProspective StudiesInfantPregnancy OutcomeAdministration, OralInfant, NewbornYoung AdultTreatment Outcome

Stichwörter der Autor:innen

all-oral 6-month MDR/RR-TB regimendrug-resistanceoutcomestuberculosis

Substanzen

Antitubercular AgentsRifampin

Autor:innen und Institutionen

  • HIV and Other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa.
  • CAPRISA-MRC HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
  • King Dinuzulu Hospital Complex, Sydenham, Durban, South Africa.
  • Divisions of General Internal Medicine and Infectious Diseases, Montefiore Medical Center, Albert Einstein College of Medicine, NewYork, New York, USA.
  • Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
  • Department of Women's and Children's Health, University of Liverpool, Liverpool, United Kingdom.

ORCID-Profile: Marian Loveday, Emma Clarence, James C M Brust, Catriona Waitt, Richard Court

Förderung

  • National Institute of Allergy and Infectious Diseases
  • NIH HHS
  • NIAID NIH HHS
  • South African Medical Research Council
  • National Institutes of Health

Zitieren

APA

Loveday, M., Clarence, E., Hlangu, S., Singh, N., Chotoo, S., Brust, J. C. M., Waitt, C., Court, R., & Furin, J. (2026). Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa. Clinical Infectious Diseases, 82(5), e1063-e1071. https://doi.org/10.1093/cid/ciag032

Vancouver

Loveday M, Clarence E, Hlangu S, Singh N, Chotoo S, Brust JCM, et al. Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa. Clinical Infectious Diseases. 2026;82(5):e1063-e1071. doi:10.1093/cid/ciag032

BibTeX
@article{Loveday2026,
  author = {Loveday, Marian and Clarence, Emma and Hlangu, Sindisiwe and Singh, Nalini and Chotoo, Sunitha and Brust, James C M and Waitt, Catriona and Court, Richard and Furin, Jennifer},
  title = {Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {5},
  pages = {e1063--e1071},
  doi = {10.1093/cid/ciag032}
}
Kostenlos starten →